As of December 31, 2024, the company had cash, cash equivalents and investments of $184.6M, which is expected to fund operating expenses and capital expenditure requirements into 2027. “We continue executing our highly differentiated Generative Phosphoproteomics AP3-enabled strategy, delivering rapid progress towards key milestones across all programs, including our clinical assets, ACR-368 and ACR-2316,” said CEO Peter Blume-Jensen. “…we continue to expand the actionable capabilities of our Generative Phosphoproteomics AP3 platform to enable us to optimize therapeutic compounds for desired pathway effects, which drives our streamlined drug discovery, design and development.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics Reports 2024 Financial Results and Progress
- Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating
- Acrivon Therapeutics price target lowered to $19 from $22 at H.C. Wainwright
- Acrivon Therapeutics, Inc. (ACRV) Q4 Earnings Cheat Sheet
- Acrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy Rating